Keywords: ACE, angiotensin-converting enzyme; AngII, angiotensinogen II; FGF, fibroblast growth factor; IH, infantile hemangiomas; RAS, renin-angiotensin system; SARS-CoV2; VEGF, vascular endothelial growth factor; hemangioma; late ulceration; mixed subtype infantile hemangioma; re-ulceration; vascular anomalies.